Biomarkers and Target Validation are the themes of ourODIN pilot and our efforts to pave the way for new downstream therapeutics.
The themes were selected in close dialogue with industry partners as the lend themselves nicely to pre-competitive and open research. In addition, they both address key barriers to early drug discovery that are difficult to overcome but are strong indicators of success in creating new medicines.
These focus areas require standardisation of experimental protocols and data management, which is best performed in an open environment and ODIN projects.
You can find a more thorough description of the overall aims of these two initial themes by following the links to the right, but in brief their aims are to:
• Discover lead biomarkers for multiple diseases.
• Drive improvements of early diagnosis, enhanced prediction of disease progression and greater application of personalised medicine - but always with the overall purpose of creating building blocks for subsequent drug discovery for pharma industry.
• Develop human model systems and evaluation methods for target validation in early drug discovery.
• Reduce off-target drug effects and maximise the chance of success of new therapies in patients.